Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 26 December 2025 - 6 January 2026

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

New York, Jan 5, 2026, 21:27 EST — Market closed AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high. The move mattered because drug and biotech names were among the day’s laggards as investors rotated into energy and financials after Venezuela headlines lifted oil-linked stocks. The NYSE Arca Pharmaceutical Index fell about 1.4% and the SPDR S&P Biotech ETF slid 1.1%, while the Health Care Select Sector SPDR ETF dipped 0.3%. Yahoo Finance AbbVie also put a near-term spotlight on its calendar, saying it will present
6 January 2026
·····
Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

New York, Jan 5, 2026, 20:16 EST — Market closed Johnson & Johnson shares ended down 1.47% at $204.31 on Monday, giving back early gains even as Wall Street analysts reiterated bullish calls on the healthcare conglomerate. StreetInsider.com The move matters because investors are heading into a dense stretch of company updates, with management set to speak at the JPMorgan Healthcare Conference next week and to deliver fourth-quarter results later this month. In a market that has leaned into cyclical names, defensive stocks like J&J often need a clean guidance message to keep money flowing in. JNJ.com+2investor.jnj.com+2 Analysts are also
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

New York, January 5, 2026, 14:35 ET — Regular session Johnson & Johnson (JNJ) stock fell about 2.2% on Monday as investors trimmed defensive healthcare names. Shares were down $4.49 at $202.86 in afternoon trading after touching a session low of $200.94, with about 4.8 million shares traded. The timing matters because early-year positioning has shifted quickly toward cyclicals, leaving traditionally steady names with less of a bid. When money flows out of defensives, big healthcare stocks can slide even without a single headline. Investors are also recalibrating around legal and earnings catalysts that can reprice a stock in a
5 January 2026
···
Johnson & Johnson stock: $1.30 dividend keeps JNJ in focus before key U.S. data and Jan. 21 earnings

Johnson & Johnson stock: $1.30 dividend keeps JNJ in focus before key U.S. data and Jan. 21 earnings

New York, January 4, 2026, 19:18 ET — Market closed Johnson & Johnson declared a quarterly dividend of $1.30 a share, putting the healthcare bellwether back on income investors’ screens ahead of Monday’s U.S. market reopen. JNJ shares ended Friday up 0.2% at $207.35, after trading between $203.77 and $207.37. Why it matters now is less about the payout itself and more about timing. Investors are stepping into the first full trading week of 2026 with a dense slate of economic releases that can reset interest-rate expectations — a key driver for dividend-paying stocks. “The market is looking for direction,”
5 January 2026
···
Johnson & Johnson stock: $1.30 dividend declared as earnings date nears

Johnson & Johnson stock: $1.30 dividend declared as earnings date nears

NEW YORK, Jan 4, 2026, 14:49 ET — Market closed Johnson & Johnson on Friday declared a quarterly cash dividend of $1.30 per share, payable March 10 to shareholders of record at the close of business on Feb. 24, the company said. The ex-dividend date — when shares begin trading without the right to that payout — is also Feb. 24. Jnj At Friday’s close, the payout implies an annual dividend yield of about 2.5%, keeping the healthcare bellwether in focus for income investors as U.S. trading resumes on Monday. Dividend schedules can influence near-term positioning when funds rebalance early-year
4 January 2026
··
Johnson & Johnson stock today: JNJ’s $1.30 dividend sets key dates — what investors watch next

Johnson & Johnson stock today: JNJ’s $1.30 dividend sets key dates — what investors watch next

NEW YORK, Jan 3, 2026, 14:19 ET — Market closed Johnson & Johnson said its board declared a quarterly cash dividend of $1.30 per share for the first quarter of 2026. JNJ shares closed Friday up $0.39, or 0.2%, at $207.35, with the ex-dividend date — the cutoff after which new buyers do not receive the payout — set for Feb. 24. Jnj The announcement matters for income-focused holders because it locks in the next set of dates for a widely held blue-chip name at the start of a new year. It also puts a fresh spotlight on “total return”
3 January 2026
··
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

NEW YORK, Jan 3, 2026, 13:21 ET — Market closed Drugmakers are lifting U.S. list prices on hundreds of medicines as 2026 begins, putting drug-pricing politics back in focus for healthcare investors. The sector finished higher in Friday’s session, the last U.S. trading day before the weekend. Drugmakers plan to raise U.S. prices on at least 350 branded medicines for 2026, including vaccines for COVID-19, RSV and shingles, as well as Pfizer’s cancer drug Ibrance, Reuters reported, citing data from healthcare research firm 3 Axis Advisors. The median list-price increase is about 4%, and the changes do not reflect rebates
3 January 2026
····
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

NEW YORK, Jan 2, 2026, 20:13 ET — Market closed Johnson & Johnson shares ended Friday up 0.19% at $207.35 after the healthcare company said its board declared a $1.30-per-share cash dividend for the first quarter of 2026. Yahoo Finance The timing matters because investors entered 2026 with markets trying to stabilize after a late-December stretch that failed to deliver the usual year-end “Santa Claus” bounce. Wall Street’s focus is shifting back to interest-rate expectations and the next round of economic data. Reuters For income-focused investors, dividends can act as a buffer in volatile tape because they provide a cash
3 January 2026
·····
Johnson & Johnson stock today: JNJ nudges lower after $1.30 dividend as earnings loom

Johnson & Johnson stock today: JNJ nudges lower after $1.30 dividend as earnings loom

New York, January 2, 2026, 12:21 ET — Regular session Johnson & Johnson shares edged lower on Friday after the healthcare conglomerate declared its first-quarter dividend, leaving the stock little changed on the first trading day of 2026. Jnj The muted reaction reflects how investors use dividend announcements less as a surprise catalyst and more as a signal of steady cash returns, particularly for a large, widely held defensive name like J&J. That matters now because rate expectations often shape demand for dividend stocks: when investors expect rates to fall, a stable payout can look more attractive relative to safer
2 January 2026
···
Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

NEW YORK, January 1, 2026, 12:08 ET — Market closed. Johnson & Johnson shares were steady heading into 2026, last closing up 0.02% at $206.95 on Wednesday, with U.S. stock markets shut on Thursday for the New Year’s Day holiday. New York Stock Exchange Why it matters now: investors are starting the year with U.S. drug pricing back on the agenda after Reuters reported drugmakers plan to raise list prices on at least 350 branded medicines in 2026, even as the Trump administration presses for cuts. Reuters For Johnson & Johnson, attention is also turning to Jan. 21, when CEO
1 January 2026
·
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

NEW YORK, December 31, 2025, 8:48 PM ET — Market closed Johnson & Johnson (JNJ) shares eked out a 0.02% gain to $206.95 on Wednesday, a rare green finish as U.S. stocks slipped in the final session of 2025. The S&P 500 fell 0.74% and the Dow lost 0.63%. MarketWatch The muted close leaves investors searching for a clean catalyst after a strong year for the stock. The next big read comes when management updates guidance and lays out how recent deals will flow through earnings. That focus sharpened this week after the company said it completed its $3.05 billion
1 January 2026
··
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

NEW YORK, December 30, 2025, 18:51 ET — After-hours Johnson & Johnson (JNJ) shares edged lower in after-hours trading on Tuesday after the healthcare conglomerate said it had completed its acquisition of Halda Therapeutics. The stock was down 0.3% at $206.91. The completion matters because investors are resetting portfolios into year-end with interest rates back in focus and dealmaking under a brighter spotlight. For J&J, the question is whether a new oncology platform can expand its pipeline without pressuring near-term profit metrics. The timing also pushes the spotlight onto management’s next set of targets. With the company set to talk
31 December 2025
··
Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

NEW YORK, December 30, 2025, 12:44 ET — Regular session Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain one-time items — split between 2025 and 2026. Johnson & Johnson Investor Relations The closing gives J&J a new platform aimed at developing oral, targeted cancer
30 December 2025
··
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

NEW YORK, December 29, 2025, 20:26 ET — Market closed Johnson & Johnson (JNJ) shares were last down 0.02% at $207.56 on Monday after the healthcare conglomerate said it completed its $3.05 billion cash acquisition of cancer drug developer Halda Therapeutics. The stock traded between $207.31 and $209.46, and J&J said it will account for the deal as a business combination and expects it to cut adjusted earnings per share by about $0.20, split evenly between the fourth quarter and 2026. JNJ.com The closing matters because it adds another pipeline bet in oncology, where big drugmakers are still hunting for
30 December 2025
····
JNJ stock edges higher after Johnson & Johnson closes $3.05B Halda deal; earnings outlook next

JNJ stock edges higher after Johnson & Johnson closes $3.05B Halda deal; earnings outlook next

NEW YORK, December 29, 2025, 14:38 ET — Regular session Johnson & Johnson shares were up about 0.3% at $208.28 in afternoon trading on Monday after the healthcare conglomerate said it had completed its $3.05 billion cash acquisition of Halda Therapeutics. JNJ.com The close matters because it brings Johnson & Johnson a clinical-stage oncology platform and assets as investors press large drugmakers to keep replenishing their pipelines ahead of patent expirations and pricing pressure. It also puts the focus back on execution: the deal is expected to dent near-term profit metrics, and Johnson & Johnson has flagged its next earnings
29 December 2025
···
Dow slips from record close as tech rally cools in year-end trade

Dow slips from record close as tech rally cools in year-end trade

NEW YORK, December 29, 2025, 10:30 ET — Regular session. The Dow Jones Industrial Average slipped on Monday as heavyweight technology shares gave back some of last week’s gains, pulling the blue-chip index off its recent highs. By 9:35 a.m. ET, the Dow was down 66.86 points, or 0.14%, at 48,645.62. Reuters The move matters because the final week of the year typically brings lighter trading volume, which can exaggerate swings. U.S. markets will be closed on Thursday for New Year’s Day, and traders expect holiday-affected conditions to keep activity thin. Reuters Investors have also been eyeing whether the late-year
29 December 2025
······
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

NEW YORK, Dec. 28, 2025, 3:26 p.m. ET — Market closed Johnson & Johnson stock (NYSE: JNJ) heads into the final trading week of 2025 with U.S. markets shut for the weekend and investors sorting through a fresh pipeline headline that surfaced late Friday. With the New York Stock Exchange closed today and the next regular session set for Monday, Dec. 29, attention is shifting to what could move JNJ when trading resumes—including biotech read-throughs, litigation headlines, and year-end macro catalysts in a holiday-shortened week. New York Stock Exchange+2Investopedia+2 As of the latest available market data, JNJ last traded around
28 December 2025
··
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

NEW YORK, Dec. 27, 2025, 3:33 PM ET — Market closed Johnson & Johnson (NYSE: JNJ) stock is heading into the final trading days of 2025 with U.S. markets closed for the weekend and year-end liquidity typically thinning across Wall Street. JNJ last closed at $207.63 on Friday, down 0.07% on the day, and was last indicated around $207.86 in after-hours trading, according to widely followed market data. Investing.com+1 For investors, the key question before Monday’s open is whether the latest company-specific headline—a discontinued mid-stage eczema (atopic dermatitis) trial—changes the near-term narrative for a stock that has been trading in
27 December 2025
··
Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

NEW YORK, Dec. 27, 2025, 12:57 p.m. ET — Market closed (weekend) Healthcare stocks are heading into the final trading days of 2025 with a rare mix of “defensive” support and headline-driven volatility—exactly the combination that can matter most when liquidity is thin and investors are rebalancing portfolios into year-end. U.S. stock markets are shut today, but Friday’s post-Christmas session left a clear message: the broader market is still hovering near record levels, and investors have been widening their focus beyond mega-cap technology—an environment that can favor large-cap healthcare even as biotech remains more catalyst-sensitive. Reuters+1 Where healthcare stocks stand
27 December 2025
Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. markets reopen for a full session on Friday, Dec. 26, 2025, following the Christmas Day closure—after a holiday-shortened early close on Wednesday, Dec. 24. New York Stock Exchange+1 For Johnson & Johnson (NYSE: JNJ) investors, the post-holiday open comes with a familiar mix of defensive-stock appeal and headline risk—especially around talc litigation, Washington drug-pricing pressure, and the company’s portfolio reshaping plans. Below is a detailed, publication-ready rundown of the most important news, forecasts, and analysis to know before the bell. JNJ stock snapshot heading into Friday’s open Because U.S. markets were closed on Thursday, Dec. 25, the last meaningful
26 December 2025
·
1 2 3 4 5 6 7

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Go toTop